• Machine Learning Ranks Cancer Drugs Based On Proteome Of Tumors

    Apr 14 | Diagnostics World News | A UK company has released Drug Ranking Using Machine Learning (DRUML), an open-source ensemble of predictive models trained for drugs with different modes of action that can help clinicians pick the most appropriate cancer drugs for individual patients from among most (412 of 659) of the options now available. More
  • Researchers Pursue Early Detection of Ovarian Cancer, Foresee Possibility of At-Home Test

    Apr 13 | Diagnostics World News | A new study led by University of Minnesota Medical School researchers suggests that Pap test samples and cervical swabs may be a useful source of tumor-specific biomarkers for ovarian cancer, and the group sees potential for the development of an early detection test. More
  • Where We Stand in Realizing the Promise of Digital Pathology

    Apr 09 | Diagnostics World News | A year into COVID-19, we see that it has cast an unexpected spotlight on digital pathology. It has accelerated adoption as laboratories’ ability to operate has increasingly become tied to their digital footprint. In doing so, it has also laid the foundation for laboratories to realize the benefits of the digital transformation beyond remote work, positioning them to meet future challenges and capitalize on the opportunity ahead. More
  • Disease Trajectories Aim To Reduce Medical Misdiagnoses

    Apr 06 | Diagnostic World News | Getting a diagnosis right when diseases share symptoms or co-occur due to advanced age or unhealthy habits may require a more holistic view of the situation than can be gleaned from the typical physician-patient encounter. More
  • Follow the Money: Point-of-Care Dx, AI in Diagnostics, Data Management

    Apr 01 | Diagnostics World News | Paige nets another influx of cash for AI-based pathology, and Inflammatix closes a round for its novel immune-response diagnostics portfolio. Investments in point-of-care diagnostics and liquid biopsies. And new investment funds for late-stage companies and public health. More
  • Variants Vs. Lineages: How We Track SARS-CoV-2 Changes

    Mar 30 | Diagnostics World News | Color Health is adding its voice to calling for more granularity in how we name and track SARS-CoV-2 variants says Alicia Zhou, Chief Scientific Officer at Color. “There really is a difference between tracking variants versus tracking lineages,” Zhou told Diagnostics World. More
  • AMP Survey Shows Reimbursement Not Aligned With Molecular Test Costs

    Mar 29 | Diagnostics World News | The Association for Molecular Pathology released survey results outlining the effort required to interpret molecular tests. As the menu of—and demand for—molecular tests grow, so does the burden of effort and cost associated with interpretation and results reporting. Reimbursement isn’t keeping up, AMP claims. More
  • New Framework For Developing Polygenic Risk Scores

    Mar 25 | Diagnostics World News | Last week a research team published a 22-item framework in Nature that identifies the minimal polygenic risk score-related information that scientists should include in their studies. More
  • Screening Algorithm Flags Patients At Risk Of Suicide

    Mar 22 | Diagnostics World News | The suicide rate in the United States is increasing. Suicide prevention begins with risk identification, but it is impossible to screen all of the individuals within a healthcare system. Vanderbilt University Medical Center researchers develop an AI tool that can screen EHRs and flag at-risk patients. More
  • XPRIZE Names Winners In Rapid COVID Testing Competition

    Mar 17 | Diagnostics World News | XPRIZE has announced five winning teams in the $6M XPRIZE Rapid Covid Testing competition. Chosen by an independent panel of judges, the winning solutions are radically affordable compared to what is currently available on the market, and are comparable to commercial offerings at measuring sensitivity, specificity, and limit of detection—with a maximum turnaround time of 12 hours from sample to result. More
View more articles



Antigens & Antibodies for SARS-CoV-2 Diagnostic Kit Development

ACROBiosystems team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of high-quality antigen and antibody reagents to support the development of the diagnostic kits. The products include the high quality S trimer, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity tested on several platforms.

Click to learn more about ACRO’s hot matched antibody pairs and antigens.